1stRound non-equity support · Biotech

intES selected for 1stRound non-equity support

The regenerative medicine startup is developing intestinal tissue sheets.

intES was named among the eight teams selected for the 15th 1stRound programme, announced on 5 October 2026. The programme provides non-equity funding and business development support; the company’s individual allocation was not disclosed.

The startup is working on embryonic stem cell-derived intestinal tissue for inflammatory bowel disease. Technical adviser Akihiro Umezawa brings expertise in the manufacturing, safety and regulatory work needed to translate cell therapies into clinical practice.

Use of funds

ES-cell-derived intestinal tissue development and business support

Funding history

1stRound non-equity support · This roundUndisclosed

Sources

  1. UTokyo IPC Announces Selected Teams for the 15th Batch of 1stRoundutokyo-ipc.co.jp · Oct 5, 2026